Effect of ARB on ambulatory blood pressure and cardiovascular remodeling in hypertensives on hemodialysis
Phase 4
Completed
- Conditions
- Hypertension, end-stage renal failure on hemodialysis
- Registration Number
- JPRN-UMIN000000659
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Malignancy, acute myocardial infarction/unstable angina, collagen diseases, acute renal failure, severe liver disorder, history of hypersensitivity to the administered ARB, pregnant women, or women suspected of being pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Ambulatory BP monitering (mean BP, BP and HR variability) 2) UCG, carotid echogram (IVSd, LVDd, LVPWd, LVDs, FS, EF, E/A, DcT, LAD, IMT) 3) ABI/baPWV 4) Blood chemistry Endocrine: catecholamine, ANP, BNP, PRA, PAC Coagulation: fibrinogen Glucose: blood glucose, IRI Serological: CRP Oxidative stress: adiponectin, MDA-LDL, AGE
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ARB-induced cardiovascular remodeling in hemodialysis patients with hypertension?
How does ARB therapy compare to standard-of-care antihypertensives in managing ambulatory blood pressure for end-stage renal failure patients on hemodialysis?
Are there specific biomarkers that predict response to ARB treatment in hypertensive individuals undergoing hemodialysis?
What adverse events are associated with ARB use in patients with end-stage renal disease and hypertension, and how can they be managed effectively?
What combination therapies or alternative drug classes show promise in addressing cardiovascular remodeling alongside ARBs for hemodialysis patients with hypertension?